Consensus-Based Recommendations for the Diagnosis, Treatment, and Monitoring of Hypoparathyroidism: Insights from the DACH Region

DACH expert consensus (hypoparathyroidism) · 2025 · DACH

Source and licence

Authors: Elena Tsourdi, Karin Amrein, Christian Meier et al.
Title: Consensus-Based Recommendations for the Diagnosis, Treatment, and Monitoring of Hypoparathyroidism: Insights from the DACH Region
Journal: Calcified Tissue International, 2025
DOI: 10.1007/s00223-025-01414-5
Licence: CC BY 4.0
Changes: Verbatim excerpts; formatting adapted

Full text retrieved 2026-10-27 from Europe PMC · PMC12343711

Licence statement of the original publication

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.

Open the original publication →Full text on Europe PMC

Recommendations

Verbatim, with grade of recommendation or strength of consensus where given.

Etiology and diagnoses

1. In at least 90% of all chronic hypoPT, surgery is the causeConsensus: ↑↑
2. Paresthesia, muscle cramps and fatigue are the most common symptoms of HypoPTConsensus: ↑↑
3. Albumin-adjusted serum calcium measurement for diagnosis can be performed 12–24 h post-surgically, within 2 weeks postoperatively and every 3–6 months thereafterConsensus: ↑
4. The diagnosis requires a combination of serum albumin-adjusted calcium and serum parathyroid hormone levelsConsensus: ↑↑
5. There are no generally recognized threshold values for parathyroid hormone levelsConsensus: ↑

Treatment

6. Serum albumin-adjusted calcium in the lower normal range, freedom from symptoms and quality of life equivalent to age and gender controls are the most important short-term goals in chronic HypoPTConsensus: ↑↑
7. Avoiding hypo- and hypercalcemia and preventing complications are the most important long-term goals in the treatment of chronic HypoPTConsensus: ↑↑
8. The four most common reasons for the failure of therapy with calcium and active vitamin D are: Persistent symptoms and/or need for hospitalization Serum albumin-adjusted calcium levels outside the target range Intolerance to current treatment with calcium and active vitamin D Urine calcium outside the target rangeConsensus: ↑

Monitoring

9. Quality of life measurements using validated questionnaires are relevant for therapy monitoringConsensus: ↑↑
10. For quality of life measurements in HypoPT, a questionnaire specifically designed and validated for the disease would be importantConsensus: ↑↑
11. Urine calcium/creatinine values should be measured at least once a yearConsensus: ↑↑
12. In the first year of PTH replacement therapy, after reaching a stable state without dose adjustments, the therapy should be monitored quarterly and adjusted if necessaryConsensus: ↑↑

Abstract

Hypoparathyroidism (HypoPT) is a rare endocrine disorder characterized by low parathyroid hormone (PTH) levels, hypocalcemia, hyperphosphatemia, reduced active vitamin D (1,25-OH2 vitamin D), and hypercalciuria. Due to its rarity, non-specialized physicians often lack experience managing HypoPT. To address this, expert consensus statements were developed for the DACH region (Germany, Austria, Switzerland), considering regional differences and high HypoPT incidence. These statements aim to enhance adherence to guideline recommendations and improve non-specialist knowledge. From December 2023 to April 2024, three rounds of a Delphi consensus survey were conducted with seven DACH-region clinical experts. Consensus was defined as agreement among at least 6 of 7 participants (85%). Experts agreed surgery accounts for 90% of chronic HypoPT cases. Common symptoms include paresthesia, muscle cramps, and fatigue. Albumin-adjusted serum calcium should be measured 12–24 h post-surgically, within 2 weeks, and every 3–6 months thereafter. Key treatment goals are maintaining albumin-adjusted serum calcium in the lower normal range, symptom control, and quality of life. Long-term objectives include avoiding hypo- and hypercalcemia phases and disease-related complications. Failure of calcium and active vitamin D therapy is defined by persistent symptoms, hospitalization, laboratory values outside of the normal range, or medication intolerance. Experts emphasized using HypoPT-specific, validated quality-of-life questionnaires. This consensus provides practical guidance for non-specialists in diagnosing, treating, and monitoring HypoPT, improving care in German-speaking regions.

Supplementary Information: The online version contains supplementary material available at 10.1007/s00223-025-01414-5.

Contents of the original publication

The section headings of the original.

Introduction
Materials and Methods
Study Design
Questionnaires for the Three Delphi Rounds and Consensus Building
Data Analysis
Results
Delphi Experts
Etiology and Diagnoses
Treatment
Monitoring
Discussion
Conclusion

A question about this guideline?

Medelix answers clinical questions from guidelines and studies – every statement with its source.

Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint